The underlying molecular changes in the BCR::ABL1-like ALL remain of significant interest due to the possibility of incorporation of targeted therapy with tyrosine kinase inhibitors (TKI) and JAK inhibitors [13, 14]. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.